Hepatitis E virus infections in Europe.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
11 2019
Historique:
received: 02 08 2019
accepted: 06 09 2019
pubmed: 20 9 2019
medline: 20 6 2020
entrez: 20 9 2019
Statut: ppublish

Résumé

Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. The systematic use of improved tools for diagnosing and genotyping has completely changed our understanding of the epidemiology and clinical consequences of HEV infection. Most cases of HEV in Europe arise from infected animals such as pigs, wild boar, deer and rabbits. Zoonotic HEV genotypes (HEV genotypes 3-8) are mainly food-borne or transmitted by direct contact, but recent data suggest that infection can also be water-borne or even iatrogenic throught contamined blood products. HEV-3 is the most prevalent genotype in Europe but the geographic distributions of the 3 major clades and subgenotypes (HEV-3abjkchi, HEV-3efg, and HEV-3ra) differ. Most HEV-3 infections are asymptomatic but they can result in severe acute hepatitis in patients with chronic liver disease, chronic hepatitis in immunocompromised patients, and to extra-hepatic manifestations. Despite more frequent reports of symptomatic hepatitis E cases across Europe, systems for monitoring HEV infections vary greatly. Severe HEV-associated illnesses, hospitalizations and deaths are probably underestimated. The seroprevalence and incidence of locally acquired hepatitis E varies between and within European countries and over time. The precise origin of these variations is uncertain but may be linked to environmental factors or the degree to which HEV contaminates the human food chain. Collaborative initiatives such as the establishment of the One Health platform for HEV sequences (HEVnet database) will be very useful for a better understanding of the epidemiology of HEV in Europe and the development of effective prevention strategies.

Identifiants

pubmed: 31536936
pii: S1386-6532(19)30209-4
doi: 10.1016/j.jcv.2019.09.004
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-26

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Jacques Izopet (J)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France. Electronic address: izopet.j@chu-toulouse.fr.

Pauline Tremeaux (P)

APHP, Hôpital Cochin, Laboratoire de Virologie, F-75679, France.

Olivier Marion (O)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.

Marion Migueres (M)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.

Nicolas Capelli (N)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.

Sabine Chapuy-Regaud (S)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.

Jean-Michel Mansuy (JM)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France.

Florence Abravanel (F)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.

Nassim Kamar (N)

INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France; CHU Toulouse, Hôpital Rangueil, Department of Nephrology, Dialysis and Organ Transplantation, F-31300, France.

Sébastien Lhomme (S)

CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH